Kaletra
Drug
AbbVie, Inc.
Total Payments
$66,158
Transactions
6
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $522.20 | 2 | 2 |
| 2017 | $65,635 | 4 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $64,635 | 3 | 97.7% |
| Space rental or facility fees (teaching hospital only) | $1,000 | 1 | 1.5% |
| Consulting Fee | $500.00 | 1 | 0.8% |
| Food and Beverage | $22.20 | 1 | 0.0% |
Payments by Type
Research
$64,635
3 transactions
General
$1,522
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A12-562 | AbbVie, Inc. | $63,802 | 0 |
Ad
Manufacturing Companies
- AbbVie, Inc. $66,158
Product Information
- Type Drug
- Total Payments $66,158
- Total Doctors 3
- Transactions 6
About Kaletra
Kaletra is a drug associated with $66,158 in payments to 3 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is AbbVie, Inc..
Payment data is available from 2017 to 2019. In 2019, $522.20 was paid across 2 transactions to 2 doctors.
The most common payment nature for Kaletra is "Unspecified" ($64,635, 97.7% of total).
Kaletra is associated with 1 research study, including "A12-562" ($63,802).